NCT01477606已完成2 期
Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication
University of Ulm55 个研究点 分布在 2 个国家目标入组 451 人开始时间: 2012年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 451
- 试验地点
- 55
- 主要终点
- Event-free Survival
研究概览
简要总结
This is a phase II, single-arm, open-label, multi-center study in adult patients with Acute Myeloid Leukemia (AML) and FLT3-ITD as defined in inclusion/exclusion criteria.
The primary efficacy object is to evaluate the impact of midostaurin given in combination with intensive induction, consolidation including allogeneic hematopoietic stem cell transplantation and single agent maintenance therapy on event-free survival (EFS) in adult patients with AML exhibiting a FLT3-ITD.
Sample size: 440 patients
The treatment duration of an individual patient is between 18 and 24 months. Duration of the study for an individual patient including treatment (induction, consolidation [chemotherapy or allogeneic SCT], maintenance and follow-up period: Maximum 8 years
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with suspected diagnosis of AML or related precursor neoplasm, or acute leukemia of ambiguous lineage (classified according to the World Health Organization (WHO) 2008 classification)
- •Presence of FLT3-ITD assessed in the central AMLSG reference laboratories
- •Patients considered eligible for intensive chemotherapy
- •WHO performance status of ≤ 2
- •Age ≥ 18 years and ≤ 70 years
- •No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis (≤ 7 days)
- •Non-pregnant and non-nursing. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to registration ("Women of childbearing potential" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months)
- •Female patients in the reproductive age and male patients must agree to avoid getting pregnant or to father a child while on therapy and for 5 months after the last dose of chemotherapy
- •Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal ligation, or partner's vasectomy). Hormonal contraception is an inadequate method of birth control
- •Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy (while on therapy and for 5 months after the last dose of chemotherapy)
- •Signed written informed consent.
排除标准
- •AML with the following recurrent genetic abnormalities (according to WHO 2008): AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 AML with t(15;17)(q22;q12); PML-RARA (or variant translocations with other RARA gene fusions)
- •Performance status WHO >2
- •Patients with ejection fraction < 50% by MUGA or ECHO scan within 14 days of day 1
- •Organ insufficiency (creatinine >1.5x upper normal serum level; bilirubin, AST or ALP >2.5x upper normal serum level, not attributable to AML; heart failure NYHA III/IV; severe obstructive or restrictive ventilation disorder)
- •Uncontrolled infection
- •Severe neurological or psychiatric disorder interfering with ability of giving an informed consent
- •Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year
- •Known positive for HIV; active HBV, HCV, or Hepatitis A infection
- •Bleeding disorder independent of leukemia
- •No consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician and/or other physicians involved in the treatment of the patient about study participation.
- •No consent for biobanking.
研究组 & 干预措施
Midostaurin
Experimental
干预措施: Midostaurin (Drug)
Midostaurin
Experimental
干预措施: Cytarabine (Drug)
Midostaurin
Experimental
干预措施: Daunorubicin (Drug)
结局指标
主要结局
Event-free Survival
时间窗: 8years
To perform two predefined subgroup analyses in the age-groups 18-60 years and 61-70 years evaluating the impact of midostaurin given in combination with intensive induction, consolidation including allogeneic hematopoietic stem cell transplantation and single agent maintenance therapy on event-free survival (EFS) in adult patients with AML exhibiting a FLT3-ITD.
次要结局
- overall survival(8 years)
- cumulative incidence of death in CR(8 years)
- Target (FLT3) inhibition by measuring the FLT3 plasma inhibitory activity(8 years)
- Rate of early deaths and hypoplastic deaths (ED/HD)(two months)
- Rate of complete remission (CR)(Two months)
- Cumulative incidence of relapse(8 years)
- Quality of life(5 years)
- Death in CR(8 years)
- Impact of allogeneic HSCT(8 years)
- Relapse-free survival(8 years)
- Toxicities(between 18 and 24 months)
研究者
Prof. Dr. Hartmut Doehner
Prof. Dr. Hartmut Doehner
University of Ulm
研究点 (55)
Loading locations...
相似试验
撤回
2 期
iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)Acute Myeloid LeukemiaNCT03207334University of Florida
进行中（未招募）
2 期
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AMLFLT3-mutated Acute Myeloid LeukemiaNCT03591510Novartis Pharmaceuticals22
进行中（未招募）
1 期
Phase-II study evaluating midostaurin in induction, consolidation andmaintenance therapy also after allogeneic blood stem cell transplantationin patients with newly diagnosed acute myeloid leukemia exhibiting a FLT3 internal tandem duplication AMLSG 16-10EUCTR2011-003168-63-DEniversity Hospital Ulm440
进行中（未招募）
1 期
Phase-II study evaluating midostaurin in induction, consolidation andmaintenance therapy also after allogeneic blood stem cell transplantationin patients with newly diagnosed acute myeloid leukemia exhibiting a FLT3 internal tandem duplication AMLSG 16-10EUCTR2011-003168-63-ATniversity Hospital Ulm440
终止
2 期
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell TransplantationAcute Myeloid Leukemia, AdultNCT03951961University of Jena1